Porrata Luis F, Inwards David J, Ansell Stephen M, Micallef Ivana N, Johnston Patrick B, Hogan William J, Markovic Svetomir N
Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Bone Marrow Res. 2013;2013:658371. doi: 10.1155/2013/658371. Epub 2013 Apr 28.
Day 100 prognostic factors of postautologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) to predict clinical outcome in classical Hodgkin lymphoma (cHL) patients have not been evaluated. Thus, we studied if the day 100 peripheral blood absolute lymphocyte/monocyte ratio (Day 100 ALC/AMC) affects clinical outcomes by landmark analysis from day 100 post-APBHSCT. Only cHL patients achieving a complete remission at day 100 post-APBHSCT were studied. From 2000 to 2010, 131 cHL consecutive patients qualified for the study. The median followup from day 100 was 4.1 years (range: 0.2-12.3 years). Patients with a Day 100 ALC/AMC ≥ 1.3 experienced superior overall survival (OS) and progression-free survival (PFS) compared with Day 100 ALC/AMC < 1.3 (from day 100: OS, median not reached versus 2.8 years; 5 years OS rates of 93% (95% CI, 83%-97%) versus 35% (95% CI, 19%-51%), resp., P < 0.0001; from day 100: PFS, median not reached versus 1.2 years; 5 years PFS rates of 79% (95% CI, 69%-86%) versus 27% (95% CI, 14%-45%), resp., P < 0.0001). Day ALC/AMC ratio was an independent predictor for OS and PFS. Thus, Day 100 ALC/AMC ratio is a simple biomarker that can help to assess clinical outcomes from day 100 post-APBHSCT in cHL patients.
自体外周血造血干细胞移植（APBHSCT）后100天的预后因素对经典型霍奇金淋巴瘤（cHL）患者临床结局的预测作用尚未得到评估。因此，我们通过对APBHSCT后100天进行标志性分析，研究了第100天外周血绝对淋巴细胞/单核细胞比值（第100天ALC/AMC）是否会影响临床结局。仅对在APBHSCT后第100天实现完全缓解的cHL患者进行了研究。2000年至2010年，131例连续的cHL患者符合研究条件。从第100天开始的中位随访时间为4.1年（范围：0.2 - 12.3年）。与第100天ALC/AMC < 1.3的患者相比，第100天ALC/AMC≥1.3的患者总生存期（OS）和无进展生存期（PFS）更佳（从第100天起：OS，中位生存期未达到对比2.8年；5年OS率分别为93%（95%CI，83% - 97%）对比35%（95%CI，19% - 51%），P < 0.0001；从第100天起：PFS，中位生存期未达到对比1.2年；5年PFS率分别为79%（95%CI，69% - 86%）对比27%（95%CI，14% - 45%），P < 0.0001）。第100天ALC/AMC比值是OS和PFS的独立预测因素。因此，第100天ALC/AMC比值是一种简单的生物标志物，可有助于评估cHL患者APBHSCT后第100天的临床结局。
